Zoetis Inc. (FRA:ZOE)
Germany
· Delayed Price · Currency is EUR | Market Cap | 57.67B |
| Revenue (ttm) | 7.99B |
| Net Income (ttm) | 2.22B |
| Shares Out | n/a |
| EPS (ttm) | 4.95 |
| PE Ratio | 25.93 |
| Forward PE | 23.39 |
| Dividend | 1.75 (1.36%) |
| Ex-Dividend Date | Jul 18, 2025 |
| Volume | n/a |
| Average Volume | 111 |
| Open | 129.80 |
| Previous Close | 130.32 |
| Day's Range | 129.80 - 129.80 |
| 52-Week Range | 124.94 - 179.60 |
| Beta | n/a |
| RSI | 48.89 |
| Earnings Date | Aug 5, 2025 |
About Zoetis
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other ph... [Read more]
Financial Performance
In 2024, Zoetis's revenue was $9.26 billion, an increase of 8.33% compared to the previous year's $8.54 billion. Earnings were $2.49 billion, an increase of 6.06%.
Financial numbers in USD Financial StatementsNews
Zoetis Announces Pricing of $1.85 Billion of Senior Notes
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that it has agreed to sell $1.850 billion of senior notes, consisting of $850.0 million aggregate princ...
Zoetis Announces Pricing of $1.85 Billion of Senior Notes
Zoetis Inc. (NYSE:ZTS) today announced that it has agreed to sell $1.850 billion of senior notes, consisting of $850.0 million aggregate principal amount of 4.150% senior notes due 2028 and $1.0 billi...
If You'd Invested $1,000 in Zoetis (ZTS) Stock 10 Years Ago, Here's How Much You'd Have Today
The short-term picture has been less rosy than the longer-term one.
.jpeg?width=1200&auto=webp&crop=3%3A2)
ZOE's Dr Federica Amati: 'Taking the Tube is the unhealthiest part of my day — the pollutants are awful'
Waking up with water, a sauna at lunchtime and putting together a healthy meal are the doctor’s wellbeing secrets
Top 50 High-Quality Dividend Stocks For August 2025
My investable universe of 50 high-quality dividend growth stocks aims to identify attractive opportunities based on valuation and future return potential. Currently, 20 stocks offer an estimated futur...
Zoetis CEO: It's unclear if animal health will be a part of pharmaceutical tariffs
Kristin Peck, Zoetis CEO, joins 'Closing Bell: Overtime' to discuss Q2 earnings, tariff impact on business and domestic production.
Zoetis CEO: It's unclear if animal health will be a part of pharmaceutical tariffs
Kristin Peck, Zoetis CEO, joins 'Closing Bell: Overtime' to discuss Q2 earnings, tariff impact on business and domestic production.
Zoetis raises 2025 organic operational revenue growth guidance to up to 8% while advancing key franchises
Zoetis Inc. 2025 Q2 - Results - Earnings Call Presentation
Zoetis Inc. (ZTS) Q2 2025 Earnings Call Transcript
Zoetis Lifts Outlook As Companion Animal Portfolio Offsets Librela Decline
Animal health firm Zoetis Inc. ZTS on Tuesday reported a second-quarter 2025 adjusted earnings per share of $1.76, up from $1.56 a year ago, beating the consensus of $1.61.
Zoetis Surges After Crushing Expectations And Raising Its Outlook
Zoetis stock surged early Tuesday after the animal-health company beat quarterly forecasts, leading to a guidance hike.
Zoetis rises after Q2 beat as earnings outlook tops consensus
Animal healthcare firm Zoetis raises annual forecast on strong pet product demand
Zoetis raised annual forecast and beat second-quarter estimates on Tuesday, driven by strong demand for its medicines and vaccines for pets, sending the animal healthcare company's shares surging abou...
Zoetis Announces Second Quarter 2025 Results, Raises Full Year 2025 Outlook
Zoetis Inc. (NYSE:ZTS) today reported its financial results for the second quarter of 2025 and raised its full year 2025 guidance. The company reported revenue of $2.5 billion for the second quarter o...
Zoetis Announces Second Quarter 2025 Results, Raises Full Year 2025 Outlook
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today reported its financial results for the second quarter of 2025 and raised its full year 2025 guidance. The company...
Zoetis Q2 2025 Earnings Preview
Top 15 High-Growth Dividend Stocks For August 2025
My Top 15 High-Growth Dividend Stock list underperformed in July, but remains ahead of VIG and SPY year-to-date, with an 8.75% return. The watchlist targets a 12% long-term annualized return; July's l...
How Do Investors Really Feel About Zoetis?
Zoetis's (NYSE: ZTS) short percent of float has fallen 14.56% since its last report. The company recently reported that it has 7.85 million shares sold short , which is 1.76% of all regular shares th...
Zoetis: Poised For Growth Yet Priced For Decline (Rating Upgrade To Strong Buy)
Phibro's Feed Play Pays Off: JPMorgan Upgrades On Zoetis Deal Boost
JPMorgan upgraded Phibro Animal Health Corporation (NASDAQ: PAHC), citing strong execution following its $350 million acquisition of Zoetis' medicated feed additive and water-soluble product portfoli...
Zoetis: Growth To Continue Thanks To Companion Animals
Zoetis to Host Webcast and Conference Call on Second Quarter 2025 Financial Results
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, August 5, 2025. Chief Executive Officer Kristin P...
Elanco Animal Health Gets Its Bite Back, Pipeline Efforts Earn Praise
After years of struggling with market share losses and uneven execution, Elanco Animal Health Incorporated (NYSE: ELAN) appears to be turning a corner . What Happened : Investor meetings hosted by Wi...
Joseph: Were exporting more from the U.S. than were importing
Wetteny Joseph, CFO of Zoetis, says tariffs are manageable and animal health remains resilient. He supports tax policies that boost innovation and sees long-term growth despite macro uncertainty.